+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

Sterile Injectable Drugs Market by Molecule Type, Drug, Indication, Distribution - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 183 Pages
  • October 2024
  • Region: Global
  • 360iResearch™
  • ID: 6012135
UP TO OFF until Dec 31st 2024
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Sterile Injectable Drugs Market grew from USD 518.49 billion in 2023 to USD 568.62 billion in 2024. It is expected to continue growing at a CAGR of 10.17%, reaching USD 1.02 trillion by 2030.

Sterile injectable drugs are formulations that are administered directly into the body through injection. This segment primarily includes vaccines, antibiotics, monoclonal antibodies, and insulin, characterized by their necessity in providing rapid therapeutic effects. These drugs are crucial due to their requirement in critical care settings, where swift therapeutic action is paramount. Their applications extend across various medical fields, including oncology, cardiology, immunology, and endocrinology. The end-use scope encompasses hospitals, clinics, home healthcare settings, and ambulatory surgical centers. Market growth is significantly influenced by increasing prevalence of chronic diseases, advancements in biologics, and a strong focus on biopharmaceuticals, driven by aging populations and lifestyle changes. The demand for precision medicine and development of novel therapies offers a fertile ground for innovation. Potential opportunities lie in advancements in drug delivery systems and increasing adoption of biosimilars, which can drastically reduce healthcare costs. However, the market faces limitations due to stringent regulatory requirements and high manufacturing costs. The complexity of biologic drug development, coupled with challenges in maintaining cold chain logistics, further complicates market dynamics. A critical area of innovation and research lies in developing technologies that enhance drug stability and delivery efficiency, such as liposomal formulations and nanoparticle carriers. Additionally, the exploration of digital therapeutics and integration with AI for improved patient outcomes provides a frontier for growth. Companies can capitalize on these innovations by fostering collaborations between pharmaceutical firms and tech companies, investing in R&D, and navigating regulatory landscapes effectively. The market is inherently competitive and highly regulated, necessitating agility and adaptability from stakeholders to successfully harness emerging trends and maintain a competitive edge.

Understanding Market Dynamics in the Sterile Injectable Drugs Market

The Sterile Injectable Drugs Market is rapidly evolving, shaped by dynamic supply and demand trends. These insights provide companies with actionable intelligence to drive investments, develop strategies, and seize emerging opportunities. A comprehensive understanding of market dynamics also helps organizations mitigate political, geographical, technical, social, and economic risks while offering a clearer view of consumer behavior and its effects on manufacturing costs and purchasing decisions.
  • Market Drivers
    • Increasing prevalence of chronic diseases among population
    • Significant benefits and efficacy of sterile injectable drugs
    • Rise in healthcare spending and improved healthcare facilities
  • Market Restraints
    • High costs associated with sterile injectable drug manufacturing
  • Market Opportunities
    • Development of novel formulations and delivery methods
    • Growing expansion of sterile injectable drug manufacturing facilities
  • Market Challenges
    • Stringent approval and certification processes

Exploring Porter’s Five Forces for the Sterile Injectable Drugs Market

Porter’s Five Forces framework further strengthens the insights of the Sterile Injectable Drugs Market, delivering a clear and effective methodology for understanding the competitive landscape. This tool enables companies to evaluate their current competitive standing and explore strategic repositioning by assessing businesses’ power dynamics and market positioning. It is also instrumental in determining the profitability of new ventures, helping companies leverage their strengths, address weaknesses, and avoid potential pitfalls.

Applying PESTLE Analysis to the Sterile Injectable Drugs Market

External macro-environmental factors deeply influence the performance of the Sterile Injectable Drugs Market, and the PESTLE analysis provides a comprehensive framework for understanding these influences. By examining Political, Economic, Social, Technological, Legal, and Environmental elements, this analysis offers organizations critical insights into potential opportunities and risks. It also helps businesses anticipate changes in regulations, consumer behavior, and economic trends, enabling them to make informed, forward-looking decisions.

Analyzing Market Share in the Sterile Injectable Drugs Market

The Sterile Injectable Drugs Market share analysis evaluates vendor performance. This analysis provides a clear view of each vendor’s standing in the competitive landscape by comparing key metrics such as revenue, customer base, and other critical factors. Additionally, it highlights market concentration, fragmentation, and trends in consolidation, empowering vendors to make strategic decisions that enhance their market position.

Evaluating Vendor Success with the FPNV Positioning Matrix in the Sterile Injectable Drugs Market

The Sterile Injectable Drugs Market FPNV Positioning Matrix is crucial in evaluating vendors based on business strategy and product satisfaction levels. By segmenting vendors into four quadrants - Forefront (F), Pathfinder (P), Niche (N), and Vital (V) - this matrix helps users make well-informed decisions that best align with their unique needs and objectives in the market.

Strategic Recommendations for Success in the Sterile Injectable Drugs Market

The Sterile Injectable Drugs Market strategic analysis is essential for organizations aiming to strengthen their position in the global market. A comprehensive review of resources, capabilities, and performance helps businesses identify opportunities for improvement and growth. This approach empowers companies to navigate challenges in the increasingly competitive landscape, ensuring they capitalize on new opportunities and align with long-term success.

Key Company Profiles

The report delves into recent significant developments in the Sterile Injectable Drugs Market, highlighting leading vendors and their innovative profiles. These include Adare Pharma Solutions, Aenova Group, Almac Group, Avara Pharmaceutical Services, Inc., Baxter International Inc., Boehringer Ingelheim International GmbH, Catalent, Inc., CordenPharma, Eli Lilly and Company, Evonik Industries AG, F. Hoffmann-La Roche Ltd, FAMAR Health Care Services, Fresenius Kabi Ag, Grifols S.A., Hikma Pharmaceuticals PLC, Jubilant Pharmova Limited, Lonza, Nexus Pharmaceuticals, Inc., Patheon, Inc. (Thermo Fischer), Pfizer Inc., Recipharm AB, and Siegfried Holding AG.

Market Segmentation & Coverage

This research report categorizes the Sterile Injectable Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:
  • Molecule Type
    • Large Molecule
    • Small Molecule
  • Drug
    • Blood Factors
    • Cytokines
    • Immunoglobulins
    • Insulin
    • Monoclonal Antibodies (mAbs)
    • Peptide Hormones
    • Vaccine
  • Indication
    • Autoimmune Diseases
    • Cardiovascular & Metabolic Diseases
    • Gastroenterology
    • Hematology
    • Infectious Diseases
    • Neurology
    • Oncology
  • Distribution
    • E-commerce
    • Hospital Pharmacy
    • Retail Pharmacy
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report provides a detailed overview of the market, exploring several key areas:

  1. Market Penetration: A thorough examination of the current market landscape, featuring comprehensive data from leading industry players and analyzing their reach and influence across the market.
  2. Market Development: The report identifies significant growth opportunities in emerging markets and assesses expansion potential within established segments, providing a roadmap for future development.
  3. Market Diversification: In-depth coverage of recent product launches, untapped geographic regions, significant industry developments, and strategic investments reshaping the market landscape.
  4. Competitive Assessment & Intelligence: A detailed analysis of the competitive landscape, covering market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, technological advancements, and innovations in manufacturing by key market players.
  5. Product Development & Innovation: Insight into groundbreaking technologies, R&D efforts, and product innovations that will drive the market in future.

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

  1. What is the current size of the market, and how is it expected to grow?
  2. Which products, segments, and regions present the most attractive investment opportunities?
  3. What are the prevailing technology trends and regulatory factors influencing the market?
  4. How do top vendors rank regarding market share and competitive positioning?
  5. What revenue sources and strategic opportunities guide vendors' market entry or exit decisions?

Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report

Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing prevalence of chronic diseases among population
5.1.1.2. Significant benefits and efficacy of sterile injectable drugs
5.1.1.3. Rise in healthcare spending and improved healthcare facilities
5.1.2. Restraints
5.1.2.1. High costs associated with sterile injectable drug manufacturing
5.1.3. Opportunities
5.1.3.1. Development of novel formulations and delivery methods
5.1.3.2. Growing expansion of sterile injectable drug manufacturing facilities
5.1.4. Challenges
5.1.4.1. Stringent approval and certification processes
5.2. Market Segmentation Analysis
5.3. Porter’s Five Forces Analysis
5.3.1. Threat of New Entrants
5.3.2. Threat of Substitutes
5.3.3. Bargaining Power of Customers
5.3.4. Bargaining Power of Suppliers
5.3.5. Industry Rivalry
5.4. PESTLE Analysis
5.4.1. Political
5.4.2. Economic
5.4.3. Social
5.4.4. Technological
5.4.5. Legal
5.4.6. Environmental
6. Sterile Injectable Drugs Market, by Molecule Type
6.1. Introduction
6.2. Large Molecule
6.3. Small Molecule
7. Sterile Injectable Drugs Market, by Drug
7.1. Introduction
7.2. Blood Factors
7.3. Cytokines
7.4. Immunoglobulins
7.5. Insulin
7.6. Monoclonal Antibodies (mAbs)
7.7. Peptide Hormones
7.8. Vaccine
8. Sterile Injectable Drugs Market, by Indication
8.1. Introduction
8.2. Autoimmune Diseases
8.3. Cardiovascular & Metabolic Diseases
8.4. Gastroenterology
8.5. Hematology
8.6. Infectious Diseases
8.7. Neurology
8.8. Oncology
9. Sterile Injectable Drugs Market, by Distribution
9.1. Introduction
9.2. E-commerce
9.3. Hospital Pharmacy
9.4. Retail Pharmacy
10. Americas Sterile Injectable Drugs Market
10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States
11. Asia-Pacific Sterile Injectable Drugs Market
11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam
12. Europe, Middle East & Africa Sterile Injectable Drugs Market
12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom
13. Competitive Landscape
13.1. Market Share Analysis, 2023
13.2. FPNV Positioning Matrix, 2023
13.3. Competitive Scenario Analysis
13.4. Strategy Analysis & Recommendation
LIST OF FIGURES
FIGURE 1. STERILE INJECTABLE DRUGS MARKET RESEARCH PROCESS
FIGURE 2. STERILE INJECTABLE DRUGS MARKET SIZE, 2023 VS 2030
FIGURE 3. GLOBAL STERILE INJECTABLE DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GLOBAL STERILE INJECTABLE DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL STERILE INJECTABLE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL STERILE INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2023 VS 2030 (%)
FIGURE 7. GLOBAL STERILE INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 8. GLOBAL STERILE INJECTABLE DRUGS MARKET SIZE, BY DRUG, 2023 VS 2030 (%)
FIGURE 9. GLOBAL STERILE INJECTABLE DRUGS MARKET SIZE, BY DRUG, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 10. GLOBAL STERILE INJECTABLE DRUGS MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
FIGURE 11. GLOBAL STERILE INJECTABLE DRUGS MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 12. GLOBAL STERILE INJECTABLE DRUGS MARKET SIZE, BY DISTRIBUTION, 2023 VS 2030 (%)
FIGURE 13. GLOBAL STERILE INJECTABLE DRUGS MARKET SIZE, BY DISTRIBUTION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 14. AMERICAS STERILE INJECTABLE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 15. AMERICAS STERILE INJECTABLE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 16. UNITED STATES STERILE INJECTABLE DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 17. UNITED STATES STERILE INJECTABLE DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 18. ASIA-PACIFIC STERILE INJECTABLE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 19. ASIA-PACIFIC STERILE INJECTABLE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA STERILE INJECTABLE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA STERILE INJECTABLE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 22. STERILE INJECTABLE DRUGS MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 23. STERILE INJECTABLE DRUGS MARKET, FPNV POSITIONING MATRIX, 2023
LIST OF TABLES
TABLE 1. STERILE INJECTABLE DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. GLOBAL STERILE INJECTABLE DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL STERILE INJECTABLE DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL STERILE INJECTABLE DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. STERILE INJECTABLE DRUGS MARKET DYNAMICS
TABLE 7. GLOBAL STERILE INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL STERILE INJECTABLE DRUGS MARKET SIZE, BY LARGE MOLECULE, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL STERILE INJECTABLE DRUGS MARKET SIZE, BY SMALL MOLECULE, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL STERILE INJECTABLE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL STERILE INJECTABLE DRUGS MARKET SIZE, BY BLOOD FACTORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL STERILE INJECTABLE DRUGS MARKET SIZE, BY CYTOKINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL STERILE INJECTABLE DRUGS MARKET SIZE, BY IMMUNOGLOBULINS, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL STERILE INJECTABLE DRUGS MARKET SIZE, BY INSULIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL STERILE INJECTABLE DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES (MABS), BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL STERILE INJECTABLE DRUGS MARKET SIZE, BY PEPTIDE HORMONES, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL STERILE INJECTABLE DRUGS MARKET SIZE, BY VACCINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL STERILE INJECTABLE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL STERILE INJECTABLE DRUGS MARKET SIZE, BY AUTOIMMUNE DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL STERILE INJECTABLE DRUGS MARKET SIZE, BY CARDIOVASCULAR & METABOLIC DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL STERILE INJECTABLE DRUGS MARKET SIZE, BY GASTROENTEROLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL STERILE INJECTABLE DRUGS MARKET SIZE, BY HEMATOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL STERILE INJECTABLE DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL STERILE INJECTABLE DRUGS MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL STERILE INJECTABLE DRUGS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL STERILE INJECTABLE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL STERILE INJECTABLE DRUGS MARKET SIZE, BY E-COMMERCE, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL STERILE INJECTABLE DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL STERILE INJECTABLE DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. AMERICAS STERILE INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 31. AMERICAS STERILE INJECTABLE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 32. AMERICAS STERILE INJECTABLE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 33. AMERICAS STERILE INJECTABLE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 34. AMERICAS STERILE INJECTABLE DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 35. ARGENTINA STERILE INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 36. ARGENTINA STERILE INJECTABLE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 37. ARGENTINA STERILE INJECTABLE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 38. ARGENTINA STERILE INJECTABLE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 39. BRAZIL STERILE INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 40. BRAZIL STERILE INJECTABLE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 41. BRAZIL STERILE INJECTABLE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 42. BRAZIL STERILE INJECTABLE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 43. CANADA STERILE INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 44. CANADA STERILE INJECTABLE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 45. CANADA STERILE INJECTABLE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 46. CANADA STERILE INJECTABLE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 47. MEXICO STERILE INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 48. MEXICO STERILE INJECTABLE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 49. MEXICO STERILE INJECTABLE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 50. MEXICO STERILE INJECTABLE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 51. UNITED STATES STERILE INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 52. UNITED STATES STERILE INJECTABLE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 53. UNITED STATES STERILE INJECTABLE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 54. UNITED STATES STERILE INJECTABLE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 55. UNITED STATES STERILE INJECTABLE DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 56. ASIA-PACIFIC STERILE INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 57. ASIA-PACIFIC STERILE INJECTABLE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 58. ASIA-PACIFIC STERILE INJECTABLE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 59. ASIA-PACIFIC STERILE INJECTABLE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 60. ASIA-PACIFIC STERILE INJECTABLE DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 61. AUSTRALIA STERILE INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 62. AUSTRALIA STERILE INJECTABLE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 63. AUSTRALIA STERILE INJECTABLE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 64. AUSTRALIA STERILE INJECTABLE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 65. CHINA STERILE INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 66. CHINA STERILE INJECTABLE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 67. CHINA STERILE INJECTABLE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 68. CHINA STERILE INJECTABLE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 69. INDIA STERILE INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 70. INDIA STERILE INJECTABLE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 71. INDIA STERILE INJECTABLE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 72. INDIA STERILE INJECTABLE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 73. INDONESIA STERILE INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 74. INDONESIA STERILE INJECTABLE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 75. INDONESIA STERILE INJECTABLE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 76. INDONESIA STERILE INJECTABLE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 77. JAPAN STERILE INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 78. JAPAN STERILE INJECTABLE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 79. JAPAN STERILE INJECTABLE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 80. JAPAN STERILE INJECTABLE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 81. MALAYSIA STERILE INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 82. MALAYSIA STERILE INJECTABLE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 83. MALAYSIA STERILE INJECTABLE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 84. MALAYSIA STERILE INJECTABLE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 85. PHILIPPINES STERILE INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 86. PHILIPPINES STERILE INJECTABLE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 87. PHILIPPINES STERILE INJECTABLE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 88. PHILIPPINES STERILE INJECTABLE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 89. SINGAPORE STERILE INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 90. SINGAPORE STERILE INJECTABLE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 91. SINGAPORE STERILE INJECTABLE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 92. SINGAPORE STERILE INJECTABLE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 93. SOUTH KOREA STERILE INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 94. SOUTH KOREA STERILE INJECTABLE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 95. SOUTH KOREA STERILE INJECTABLE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 96. SOUTH KOREA STERILE INJECTABLE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 97. TAIWAN STERILE INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 98. TAIWAN STERILE INJECTABLE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 99. TAIWAN STERILE INJECTABLE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 100. TAIWAN STERILE INJECTABLE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 101. THAILAND STERILE INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 102. THAILAND STERILE INJECTABLE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 103. THAILAND STERILE INJECTABLE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 104. THAILAND STERILE INJECTABLE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 105. VIETNAM STERILE INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 106. VIETNAM STERILE INJECTABLE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 107. VIETNAM STERILE INJECTABLE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 108. VIETNAM STERILE INJECTABLE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 109. EUROPE, MIDDLE EAST & AFRICA STERILE INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 110. EUROPE, MIDDLE EAST & AFRICA STERILE INJECTABLE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 111. EUROPE, MIDDLE EAST & AFRICA STERILE INJECTABLE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 112. EUROPE, MIDDLE EAST & AFRICA STERILE INJECTABLE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 113. EUROPE, MIDDLE EAST & AFRICA STERILE INJECTABLE DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 114. DENMARK STERILE INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 115. DENMARK STERILE INJECTABLE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 116. DENMARK STERILE INJECTABLE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 117. DENMARK STERILE INJECTABLE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 118. EGYPT STERILE INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 119. EGYPT STERILE INJECTABLE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 120. EGYPT STERILE INJECTABLE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 121. EGYPT STERILE INJECTABLE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 122. FINLAND STERILE INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 123. FINLAND STERILE INJECTABLE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 124. FINLAND STERILE INJECTABLE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 125. FINLAND STERILE INJECTABLE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 126. FRANCE STERILE INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 127. FRANCE STERILE INJECTABLE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 128. FRANCE STERILE INJECTABLE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 129. FRANCE STERILE INJECTABLE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 130. GERMANY STERILE INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 131. GERMANY STERILE INJECTABLE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 132. GERMANY STERILE INJECTABLE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 133. GERMANY STERILE INJECTABLE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 134. ISRAEL STERILE INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 135. ISRAEL STERILE INJECTABLE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 136. ISRAEL STERILE INJECTABLE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 137. ISRAEL STERILE INJECTABLE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 138. ITALY STERILE INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 139. ITALY STERILE INJECTABLE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 140. ITALY STERILE INJECTABLE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 141. ITALY STERILE INJECTABLE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 142. NETHERLANDS STERILE INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 143. NETHERLANDS STERILE INJECTABLE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 144. NETHERLANDS STERILE INJECTABLE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 145. NETHERLANDS STERILE INJECTABLE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 146. NIGERIA STERILE INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 147. NIGERIA STERILE INJECTABLE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 148. NIGERIA STERILE INJECTABLE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 149. NIGERIA STERILE INJECTABLE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 150. NORWAY STERILE INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 151. NORWAY STERILE INJECTABLE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 152. NORWAY STERILE INJECTABLE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 153. NORWAY STERILE INJECTABLE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 154. POLAND STERILE INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 155. POLAND STERILE INJECTABLE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 156. POLAND STERILE INJECTABLE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 157. POLAND STERILE INJECTABLE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 158. QATAR STERILE INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 159. QATAR STERILE INJECTABLE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 160. QATAR STERILE INJECTABLE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 161. QATAR STERILE INJECTABLE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 162. RUSSIA STERILE INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 163. RUSSIA STERILE INJECTABLE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 164. RUSSIA STERILE INJECTABLE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 165. RUSSIA STERILE INJECTABLE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 166. SAUDI ARABIA STERILE INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 167. SAUDI ARABIA STERILE INJECTABLE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 168. SAUDI ARABIA STERILE INJECTABLE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 169. SAUDI ARABIA STERILE INJECTABLE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 170. SOUTH AFRICA STERILE INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 171. SOUTH AFRICA STERILE INJECTABLE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 172. SOUTH AFRICA STERILE INJECTABLE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 173. SOUTH AFRICA STERILE INJECTABLE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 174. SPAIN STERILE INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 175. SPAIN STERILE INJECTABLE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 176. SPAIN STERILE INJECTABLE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 177. SPAIN STERILE INJECTABLE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 178. SWEDEN STERILE INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 179. SWEDEN STERILE INJECTABLE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 180. SWEDEN STERILE INJECTABLE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 181. SWEDEN STERILE INJECTABLE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 182. SWITZERLAND STERILE INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 183. SWITZERLAND STERILE INJECTABLE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 184. SWITZERLAND STERILE INJECTABLE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 185. SWITZERLAND STERILE INJECTABLE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 186. TURKEY STERILE INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 187. TURKEY STERILE INJECTABLE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 188. TURKEY STERILE INJECTABLE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 189. TURKEY STERILE INJECTABLE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 190. UNITED ARAB EMIRATES STERILE INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 191. UNITED ARAB EMIRATES STERILE INJECTABLE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 192. UNITED ARAB EMIRATES STERILE INJECTABLE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 193. UNITED ARAB EMIRATES STERILE INJECTABLE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 194. UNITED KINGDOM STERILE INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 195. UNITED KINGDOM STERILE INJECTABLE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 196. UNITED KINGDOM STERILE INJECTABLE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 197. UNITED KINGDOM STERILE INJECTABLE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 198. STERILE INJECTABLE DRUGS MARKET SHARE, BY KEY PLAYER, 2023
TABLE 199. STERILE INJECTABLE DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

Companies Mentioned

The leading players in the Sterile Injectable Drugs market, which are profiled in this report, include:
  • Adare Pharma Solutions
  • Aenova Group
  • Almac Group
  • Avara Pharmaceutical Services, Inc.
  • Baxter International Inc.
  • Boehringer Ingelheim International GmbH
  • Catalent, Inc.
  • CordenPharma
  • Eli Lilly and Company
  • Evonik Industries AG
  • F. Hoffmann-La Roche Ltd
  • FAMAR Health Care Services
  • Fresenius Kabi Ag
  • Grifols S.A.
  • Hikma Pharmaceuticals PLC
  • Jubilant Pharmova Limited
  • Lonza
  • Nexus Pharmaceuticals, Inc.
  • Patheon, Inc. (Thermo Fischer)
  • Pfizer Inc.
  • Recipharm AB
  • Siegfried Holding AG

Methodology

Loading
LOADING...

Table Information